Shares of Inogen Inc (NASDAQ:INGN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the five brokers that cover the stock, Zacks Investment Research reports. Five investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $59.50 for the company and are predicting that the company will post $0.07 earnings per share for the current quarter, according to Zacks. Zacks has also given Inogen an industry rank of 101 out of 265 based on the ratings given to related companies.
Inogen (NASDAQ:INGN) opened at 40.09 on Monday. The firm has a 50 day moving average of $40.11 and a 200-day moving average of $44.82. The company has a market capitalization of $787.85 million and a price-to-earnings ratio of 90.09. Inogen has a 1-year low of $29.06 and a 1-year high of $55.98.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, November 10th. The medical technology company reported $0.13 EPS for the quarter, hitting the consensus estimate of $0.13. During the same period last year, the business posted $0.11 earnings per share. The business had revenue of $40.80 million for the quarter, compared to analysts’ expectations of $36.99 million. The company’s revenue was up 38.8% compared to the same quarter last year. On average, equities research analysts anticipate that Inogen will post $0.30 earnings per share for the current fiscal year.
In other Inogen news, EVP Matt Scribner sold 4,102 shares of the stock in a transaction on Monday, December 14th. The stock was sold at an average price of $40.40, for a total value of $165,720.80. Following the sale, the executive vice president now owns 2,333 shares in the company, valued at $94,253.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Raymond Huggenberger sold 57,418 shares of the stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $43.06, for a total value of $2,472,419.08. Following the completion of the sale, the chief executive officer now owns 6,808 shares in the company, valued at approximately $293,152.48. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Inogen stock. Gerstein Fisher purchased a new stake in shares of Inogen Inc (NASDAQ:INGN) during the third quarter, according to its most recent disclosure with the SEC. The hedge fund purchased 30,132 shares of the medical technology company’s stock, valued at approximately $1,463,000. Gerstein Fisher owned approximately 0.15% of Inogen as of its most recent filing with the SEC.
INGN has been the topic of several analyst reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research note on Monday, November 2nd. Stifel Nicolaus lifted their target price on shares of Inogen from $48.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Inogen in a research note on Monday, November 30th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Inogen from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Wednesday, November 11th.
Inogen, Inc. is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen. The Inogen One G3 and G2 have up to 4.5 and five hours of battery life respectively. The Company’s Inogen One G2 is effective for nocturnal use.
For more information about research offerings from Zacks Investment Research, visit Zacks.com